Eniluracil

Summary

Eniluracil (CHEMBL355200) is a phase-3 clinical-stage small molecule; indicated across 7 conditions including colorectal adenocarcinoma and rectal cancer.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 4
• Chemistry: 136.11 Da · C6H4N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL355200
Name	Eniluracil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	43157
Molecular formula	C6H4N2O2
Molecular weight	136.11
InChIKey	JOZGNYDSEBIJDH-UHFFFAOYSA-N

SMILES: C#CC1=CNC(=O)NC1=O

IUPAC name: 5-ethynyl-1H-pyrimidine-2,4-dione

Also known as: 776C85, Eniluracil, Eniluracilo, ENILURACIL, EniluracilÊ, eniluracil, EniluracilÂ

Patent coverage: 5,700 distinct patent families (25,303 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Dihydropyrimidine dehydrogenase [NADP(+)].

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DPYD	7.85	IC50	14	nM	CHEMBL_ACT_652272

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
colorectal adenocarcinoma	3	MONDO:0005008	EFO:0000365
rectal cancer	3	MONDO:0006519	EFO:1000657
colonic neoplasm	3	MONDO:0005401	MONDO:0021063
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575
breast neoplasm	2	MONDO:0021100	MONDO:0007254
lymphoma	1	MONDO:0005062	EFO:0000574
head and neck cancer	1	MONDO:0005627	EFO:0006859

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003873	PHASE3	COMPLETED	Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer
NCT00004195	PHASE2	COMPLETED	Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer
NCT01231802	PHASE2	UNKNOWN	Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
NCT00827580	PHASE1	TERMINATED	Eniluracil Hand Foot Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).